LTIMindtree Q4 Results: Reports Modest Profit Growth of 2.6%, Declares ₹45 Final Dividend

IT services firm LTIMindtree has announced its financial results for the fourth quarter of the fiscal year 2024-25, presenting a modest rise in net profit and recommending a final dividend for its shareholders. The company released its Q4 FY25 results on Wednesday, April 23.

Financial Performance in Q4 FY25

For the quarter ending March 31, 2025, LTIMindtree posted a consolidated net profit of ₹1,129 crore. This represents a year-on-year (YoY) growth of 2.6% compared to the corresponding period last year. On a sequential basis (quarter-on-quarter), the net profit saw a 4% increase. Revenue from operations for the quarter increased 10% YoY to ₹9,772 crore. Quarter-on-quarter, revenues grew by a marginal 1%. In constant currency terms, revenues were reported to have increased by 6% YoY in the January-March 2024 period. 

Margin Performance and Deal Wins

The company's profitability margins saw a decline compared to the previous year. Earnings Before Interest and Tax (EBIT) margin for Q4 FY25 was 13.8%, down from 14.7% in the year-ago period. Gross margins also fell to 27.9% from 29.8% a year ago. Quarter-on-quarter, the EBIT margin remained stable at 13.8%. LTIMindtree clocked deals with a total contract value (TCV) of $1.6 billion for the quarter under review. This figure is higher than the $1.43 billion reported in the same quarter last year.

Final Dividend Recommendation

The Board has recommended a final dividend of ₹45 per ₹1 equity share, subject to shareholder approval at the upcoming AGM. The record date and AGM date will be announced later. If approved, the dividend will be paid within 30 days of the AGM's conclusion.

Market Reaction

Ahead of the results announcement, the LTIMindtree stock saw positive momentum,  closing in the green at ₹4537.90 per share, reflecting an increase of 5.03% against the previous close. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here